BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15361855)

  • 1. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways.
    Donninger H; Bonome T; Radonovich M; Pise-Masison CA; Brady J; Shih JH; Barrett JC; Birrer MJ
    Oncogene; 2004 Oct; 23(49):8065-77. PubMed ID: 15361855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.
    Vathipadiekal V; Saxena D; Mok SC; Hauschka PV; Ozbun L; Birrer MJ
    PLoS One; 2012; 7(1):e29079. PubMed ID: 22272227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
    May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
    Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
    Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
    BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer.
    Sunde JS; Donninger H; Wu K; Johnson ME; Pestell RG; Rose GS; Mok SC; Brady J; Bonome T; Birrer MJ
    Cancer Res; 2006 Sep; 66(17):8404-12. PubMed ID: 16951150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
    Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
    Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC
    Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression patterns that characterize advanced stage serous ovarian cancers.
    Lancaster JM; Dressman HK; Whitaker RS; Havrilesky L; Gray J; Marks JR; Nevins JR; Berchuck A
    J Soc Gynecol Investig; 2004 Jan; 11(1):51-9. PubMed ID: 14706684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Bandiera E; Rossi E; Donzelli C; Pasinetti B; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2007 Mar; 196(3):245.e1-11. PubMed ID: 17346539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.
    Sawiris GP; Sherman-Baust CA; Becker KG; Cheadle C; Teichberg D; Morin PJ
    Cancer Res; 2002 May; 62(10):2923-8. PubMed ID: 12019173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
    Liu JF; Hirsch MS; Lee H; Matulonis UA
    Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential gene expression analysis of ovarian cancer in a population isolate.
    Grazio D; Pichler I; Fuchsberger C; Zolezzi F; Guarnieri P; Heidegger H; Scherer A; Engl B; Messini S; Egarter-Vigl E; Pramstaller PP
    Eur J Gynaecol Oncol; 2008; 29(4):357-63. PubMed ID: 18714569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
    Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
    Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
    Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
    Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.